Horvais, Valérie http://orcid.org/0000-0002-2988-5952
Beurrier, Philippe
Cussac, Vincent http://orcid.org/0000-0002-8449-7995
Pan-Petesch, Brigitte http://orcid.org/0000-0001-9853-2635
Schirr-Bonnans, Solène http://orcid.org/0000-0003-4591-6197
Rose, Johann http://orcid.org/0000-0001-9389-7045
Bayart, Sophie
Ternisien, Catherine
Fouassier, Marc http://orcid.org/0000-0002-0964-0739
Sigaud, Marianne http://orcid.org/0000-0002-2005-1855
Babuty, Antoine http://orcid.org/0000-0002-9284-7094
Drillaud, Nicolas http://orcid.org/0000-0002-6500-5190
Guillet, Benoît http://orcid.org/0000-0003-2938-8013
Trossaërt, Marc http://orcid.org/0000-0003-4072-839X
Cochennec, Sabrina
Cornec, Magalie
Drugmanne, Guillaume
Galinat, Hubert
Gouin, Isabelle
Leroy, Estelle
Nedelec-Gac, Fabienne
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort
https://doi.org/10.1007/s40261-023-01323-1
Funding for this research was provided by:
Baxalta GmbH, a wholly subsidiary of Takeda Pharmaceutical Company Limited (IIR-FXX-002472)
Article History
Accepted: 29 October 2023
First Online: 30 November 2023
<!--Emphasis Type='Bold' removed-->Declarations
:
: This study was funded by Baxalta GmbH, a wholly subsidiary of Takeda Pharmaceutical Company Limited, as part of an investigator-initiated research project (IIR-FXX-002472). Baxalta GmbH played no role in the design and conduct of the study/collection, management, analysis, or interpretation of the data/preparation, writing, review, or approval of the manuscript.
: Valérie Horvais, Philippe Beurrier, Vincent Cussac, Brigitte Pan-Petesch, Solène Schirr-Bonnans, Johann Rose, Sophie Bayart, Catherine Ternisien, Marc Fouassier, Marianne Sigaud, Antoine Babuty and Nicolas Drillaud declare that they have no conflict of interest. Benoît Guillet received research grants from CSL Behring and consulting fees from CSL Behring/LFB/Takeda. Marc Trossaërt received funding from Baxalta GmbH for the Hopscotch Will I study.
: The data underlying the findings of this study are not openly available because they are sensitive. They can be obtained from the corresponding author upon reasonable request. The data are stored in a controlled access facility at Nantes University Hospital.
: Not applicable.
: The Institutional Ethics Committee approved the study protocol on 3 April 2019 (<i>Groupe Nantais d'Ethique dans le Domaine de la Santé</i>, GNEDS).
: The patient's non-objection was required for inclusion in the study. No written consent was required.
: Not applicable.
: Valérie Horvais, Solène Schirr-Bonnans and Marc Trossaërt contributed to the conception and design of the study. All of the authors contributed to the preparation of the materials and collection of the data. The analyses were performed by Valérie Horvais and Solène Schirr-Bonnans. The first draft of the manuscript was written by Valérie Horvais and all authors commented on all intermediary versions of the manuscript. All authors read and approved the final manuscript.